ABBV vs AZN
ABBV: A global biopharmaceutical leader focused on developing innovative medicines for complex diseases across immunology, oncology, neuroscience, and aesthetics. AZN: AstraZeneca is a global biopharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to transform patient outcomes.
Side-by-side fundamentals
| Metric | ABBV | AZN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $250.94 | $169.64 | |
| Market cap as of 2026-08-03 | $443.4B | $197.3B | |
| P/E as of 2026-08-03 | 122.48 | 25.47 | AZN lower |
| PEG as of 2026-08-03 | 6.59 | 2.64 | AZN lower |
| Net margin as of 2026-08-03 | +5.8% | +17.0% | AZN higher |
| Gross margin as of 2026-08-03 | +72.0% | +81.3% | AZN higher |
| Operating margin as of 2026-08-03 | +24.4% | +22.8% | ABBV higher |
| ROE as of 2026-08-03 | +95.6% | +21.7% | ABBV higher |
| ROA as of 2026-08-03 | +2.7% | +9.1% | AZN higher |
| Debt / equity as of 2026-08-03 | 49.22 | 0.64 | AZN lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.5% | +8.6% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +9.8% | AZN higher |
| Dividend yield as of 2026-08-03 | +2.8% | +1.9% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.28 | 1.34 | |
| 1-year return as of 2026-07-31 close | +32.8% | +16.7% | ABBV higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.